Weiss Ratings Reaffirms Sell (D-) Rating for Zymeworks (NASDAQ:ZYME)

Key Points

• Weiss Ratings has reaffirmed its Sell (D-) rating for Zymeworks (NASDAQ: ZYME), indicating ongoing concerns about the company's performance.
• Despite Weiss's negative outlook, other analysts have mixed views, with some, like B. Riley, upgrading Zymeworks to a Strong Buy and others downgrading it to a Buy rating.
• The company's stock has recently traded at $17.68 with a market capitalization of $1.33 billion, amidst significant ongoing clinical trials for its lead products.

Zymeworks (NASDAQ:ZYME - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by investment analysts at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

Other equities analysts have also issued reports about the stock. B. Riley upgraded shares of Zymeworks to a "strong-buy" rating in a research report on Thursday, October 9th. Wall Street Zen lowered shares of Zymeworks from a "strong-buy" rating to a "buy" rating in a research report on Sunday, October 19th. Finally, HC Wainwright upgraded shares of Zymeworks from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, October 14th. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy".

Zymeworks Stock Up 1.6%

Shares of ZYME stock traded up $0.27 during trading hours on Friday, reaching $17.68. The stock had a trading volume of 547,191 shares, compared to its average volume of 548,113. The stock has a fifty day simple moving average of $16.11. Zymeworks has a 12 month low of $9.03 and a 12 month high of $19.50. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -18.23 and a beta of 1.51.

Zymeworks (NASDAQ:ZYME - Get Free Report) last released its quarterly earnings data on Tuesday, November 8th. The company reported ($1.14) EPS for the quarter. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%. The firm had revenue of $4.40 million during the quarter.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.